patent_id,patent_date,patent_title,patent_num_times_cited_by_us_patents,cpc_subclass_ids
12428459,2025-09-30,Protein tag to induce ligand dependent degradation of protein/protein-fusions,0,A61K|C07K|C12N
12428412,2025-09-30,Acetylation writer inhibitor development and uses thereof,0,A61K|A61P|C07D|C12N
12419885,2025-09-23,Kinase inhibitors and methods of use thereof,0,A61K|A61P|C07D
12415816,2025-09-16,Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof,0,A61K|A61P|C07D
12410194,2025-09-09,Potent and selective azaindole inhibitors of CDK8 and CDK19,0,A61P|C07D
12404557,2025-09-02,Biomarkers predictive of anti-immune checkpoint response,0,A61K|C12Q|G01N
12403135,2025-09-02,"4H-pyrrolo[3,2-c]pyridin-4-one derivatives",0,A61K|A61P|C07D|C12Q
12398145,2025-08-26,Bicyclic urea kinase inhibitors and uses thereof,0,A61K|A61P|C07D
12391733,2025-08-19,Stapled intracellular-targeting antimicrobial peptides to treat infection,0,A61K|A61P|C07K|Y02A
12391671,2025-08-19,Allosteric EGFR inhibitors and methods of use thereof,0,A61K|A61P|C07D
12385099,2025-08-12,Circulating microrna signatures for ovarian cancer,0,A61P|C12Q|G16B
12377080,2025-08-05,Allosteric EGFR inhibitors and methods of use thereof,0,A61K|A61P|C07D
12371709,2025-07-29,Multifunctional nucleic acid reporter constructs,0,C12N|C12Q
12366576,2025-07-22,"Compositions, assays, and methods for direct modulation of fatty acid metabolism",0,A61K|A61P|C07K|C12Y|G01N
12365696,2025-07-22,Small-molecule focal adhesion kinase (FAK) inhibitors,0,A61K|A61P|C07D|C12Y
12365677,2025-07-22,Degraders that target proteins via KEAP1,0,A61K|C07D
12365664,2025-07-22,Small molecule inhibitors of SRC tyrosine kinase,0,A61P|C07D
12358960,2025-07-15,Selective targeting of ubiquitin- and ubiquitin-like E1-activating enzymes by structurally-stabilized peptides,0,A61K|C07K
12358918,2025-07-15,Aryl hydrocarbon receptor (AHR) activator compounds as cancer therapeutics,0,A61K|C07D|G01N
12351862,2025-07-08,Crisscross cooperative self-assembly,0,B82Y|C07H|C12Q
12344643,2025-07-01,Compositions and methods for inhibition of FOXP3,0,A61K|C07K
12337034,2025-06-24,Humanized CC chemokine receptor 4 (CCR4) antibodies and methods of use thereof,0,A61K|A61P|C07K
12331069,2025-06-17,DOT1L degraders and uses thereof,0,A61P|C07H
12331037,2025-06-17,Pyrimidines as EGFR-inhibitors and methods of treating disorders,0,A61P|C07D
12329821,2025-06-17,Degradation of bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use,0,A61K|A61P|C07D
12325725,2025-06-10,Cyclin-dependent kinase degraders and methods of use,0,A61P|C07J
12318452,2025-06-03,Degraders of WEE1 kinase,0,A61K
12313632,2025-05-27,Tepoxalin targeting of ABCB1 overexpressing cancers,0,A61K|A61P|C12Q|G01N
12297426,2025-05-13,DNA damage response signature guided rational design of CRISPR-based systems and therapies,0,A61K|A61P|C12N|C12Q
12282014,2025-04-22,Methods of identifying compounds that interfere with ERG-driven misguidance of BAF complexes in TMPRSS2-ERG driven prostate cancers,0,A61P|G01N
12281126,2025-04-22,Inhibitors of cyclin-dependent kinase 7 and uses thereof,0,A61K|A61P|C07D
12275731,2025-04-15,Azaindole inhibitors of wild-type and mutant forms of LRRK2,0,A61P|C07D
12268748,2025-04-08,Nucleic acid nanostructures crosslinked with oligolysine,0,A61K
12268739,2025-04-08,Use of toll-like receptor 2 (TLR-2) agonist for modulating human immune response,0,A61K|A61P|C12N|Y02A
12263166,2025-04-01,Methods of treating cancers having a BRCA1 and/or BRCA2 mutation(s),0,A61K|A61P|C07K|C12N|C12Y|G01N
12258560,2025-03-25,Compositions and methods for transient gene therapy with enhanced stability,0,A61K|A61P|C07K|C12N
12258409,2025-03-25,Method of assessing the efficacy of a test agent for modulating programmed death 1 (PD-1) signaling by using anti-phosphotyrosinylated PD-1 monoclonal antibodies,0,A61K|C07K|G01N
12258378,2025-03-25,"Engineered cells, T cell immune modulating antibodies and methods for using the same",0,A61K|C07K|C12N
12258323,2025-03-25,Dihydrooxadiazinones,0,A61K|A61P|C07D
12246004,2025-03-11,Therapeutic treatment of microsatellite unstable cancers,0,A61K|A61P|C12N|C12Q|C12Y
12239646,2025-03-04,Cancer diagnostic and treatment,0,A61K|A61P|C12Q|C40B|G01N
12234220,2025-02-25,Immunomodulatory compounds,0,A61K|C07D
12233128,2025-02-25,Degraders that target ALK and therapeutic uses thereof,0,A61K|A61P|C07D
12227548,2025-02-18,Use of IRE1α-XBP1 signaling pathway biomarkers for modulating immune responses,0,A61K|A61P|C07K|C12N|C12Q|C12Y|G01N|Y02A
12227501,2025-02-18,"3-amino-2-[2-(acylamino)pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one as CSNK1 inhibitors",0,A61P|C07D
12227488,2025-02-18,Small molecule degraders of Helios and methods of use,0,A61K|A61P|C07D
12202904,2025-01-21,IL-23R antagonists to reprogram intratumoral T regulatory cells into effector cells,0,A61K|A61P|C07K|C12N|G01N
12195802,2025-01-14,Universal early cancer diagnostics,0,A61P|C12N|C12Q|G01N
12195725,2025-01-14,Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity,0,A61K|A61P|C07K|C12N|C12Q|G01N
12195514,2025-01-14,Chimeric antigen receptors and methods of use thereof,0,C07K
12194080,2025-01-14,"Methods for identification, assessment, prevention, and treatment of metabolic disorders using PM20D1 and N-lipidated amino acids",0,A61K|A61P|C12N|C12Q|C12Y|G01N
12194055,2025-01-14,Solute carrier family 46 member 3 (SLC46A3) as marker for lipid-based nanoparticle cancer therapy and diagnostics,0,A61K|A61P|C12N|C12Q|G01N
12187701,2025-01-07,Taire family kinase inhibitors and uses thereof,0,A61K|C07D
12186278,2025-01-07,Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy,0,A61K|A61P
12173351,2024-12-24,DNA-tagged methanol responsive polymer for single-stranded nucleic acid production,0,C12N|C12Q
12171783,2024-12-24,Methods and compositions for targeting developmental and oncogenic programs in H3K27M gliomas,0,A61K|A61P|C07K
12168803,2024-12-17,Compositions and methods for screening and diagnosis of prostate cancer,0,A61K|A61P|C12N|C12Q|G01N
12168663,2024-12-17,Inhibitors of cyclin-dependent kinase 7 (CDK7),0,A61K|A61P|C07D
12165747,2024-12-10,Molecular spatial mapping of metastatic tumor microenvironment,0,C12N|C12Q|G01N|G16B|G16H|Y02A
12161663,2024-12-10,Compositions and methods for targeting cells,0,A61B|A61K|C08F|G01N
12161649,2024-12-10,Inhibitors of EGFR and methods of use thereof,0,A61K|A61P|C07D
12157741,2024-12-03,Macrocyclic inhibitors of DYRK1A,0,A61P|C07D
12153051,2024-11-26,Reagents for quantitative mass spectrometry,0,C07B|C07C|C07D|C07K|G01N
12152008,2024-11-26,Cyclopentaimidazolones for the treatment of cancer,0,A61K|A61P|C07D
12146196,2024-11-19,C-RAF mutants that confer resistance to RAF inhibitors,0,A61K|A61P|C12N|C12Q|C12Y|G01N
12146168,2024-11-19,Human CGAS-DNA complex and encoded protein,0,A01K|A61K|A61P|C07B|C07K|C12N|C12Y|G16B|Y02A
12139535,2024-11-12,Methods for upregulating immune responses using combinations of anti-RGMb and anti-PD-1 agents,0,A61K|A61P|C07K|C12N
12129248,2024-10-29,Chromobox protein inhibitors and uses thereof,0,A61P|C07D
12123019,2024-10-22,Uses of kinase inhibitors for inducing and maintaining pluripotency,0,C12N
12121521,2024-10-22,Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis,0,A61K|A61P
12116636,2024-10-15,Methods for evaluating tumor cell spheroids using 3D microfluidic cell culture device,0,C12M|C12N|C12Q|C12Y|G01N
12115151,2024-10-15,Method of treatment of p53 WT tumors,0,A61K|A61P|Y02A
12110292,2024-10-08,Ligands to cereblon (CRBN),0,A61P|C07D
12109266,2024-10-08,Modulating gabarap to modulate immunogenic cell death,0,A61K|A61P|C07K|C12N|G01N
12109212,2024-10-08,Methods of treating cancer having an active Wnt/β-catenin pathway,0,A61K|A61P|C07K|C12N|G01N
12103972,2024-10-01,"KIR3DL3 as an HHLA2 receptor, anti-HHLA2 antibodies, and uses thereof",0,A61K|A61P|C07K|G01N
12098154,2024-09-24,Inhibitors of cyclin-dependent kinases,0,A61K|A61P|C07D|C07K
12076390,2024-09-03,Humanized influenza monoclonal antibodies and methods of use thereof,0,A61K|A61P|C07K
12060366,2024-08-13,Bispecific degraders,0,A61K|A61P|C07D
12054787,2024-08-06,Compositions and methods comprising digital signatures to predict response and resistance to targeted therapy and immunotherapy,0,C12Q
12053476,2024-08-06,"Compounds, compositions and methods for cancer patient stratification and cancer treatment",0,A61K|A61P|C07D|G01N
12050219,2024-07-30,Modulating biomarkers such as SPP to increase tumor immunity and improve the efficacy of cancer immunotherapy,0,A61K|A61P|C07K|C12N|G01N
12048676,2024-07-30,Agents for reversing toxic proteinopathies,0,A61K|A61P|C12Q|G01N
12043870,2024-07-23,Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer,0,A61K|C12Q|G16B|Y02A
12042513,2024-07-23,Proteolysis targeting chimeric molecules (PROTACs) with functional handles and uses thereof,0,A61K|A61P|C07D|C08G
12030892,2024-07-09,CRBN modulators,0,A61K|A61P|C07D
12024567,2024-07-02,Method of treating a tumor expressing carbonic anhydrase IX (G250) by administering a G250-specific chimeric antigen receptor,1,A61K|A61P|C07K|C12N|C12Y
12023385,2024-07-02,Tunable endogenous protein degradation with heterobifunctional compounds,0,A61K|A61P|C07K|C12N|C12Y
12023308,2024-07-02,Agents for reversing toxic proteinopathies,0,A61K|A61P|C12Q|G01N
12019000,2024-06-25,Systems and methods for capturing cells,0,G01N|G02B
12018080,2024-06-25,Methods and compositions for treating cancer by targeting the CLEC2D-KLRB1 pathway,0,A61K|A61P|C07K|C12N|Y02A
12006555,2024-06-11,Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments,0,A61P|C12Q|G01N
12005073,2024-06-11,"Methods for modulating regulatory T cells, regulatory b cells, and immune responses using modulators of the april-taci interaction",0,A61K|C07K|C12N
12000843,2024-06-04,Compositions and methods for diagnosing and treating peroxisomal diseases,0,A61K|G01N
11999729,2024-06-04,Small molecule inhibition of transcription factor SALL4 and uses thereof,0,A61K|A61P|C07D
11998593,2024-06-04,Combination vaccine devices and methods of killing cancer cells,0,A61K|A61P|C07K|C12N
11982674,2024-05-14,Reagents for quantitative mass spectrometry,1,C07B|C07C|C07D|C07K|G01N
11981922,2024-05-14,Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment,0,A61K|C07K|C12N|C12Q|G01N
11971411,2024-04-30,Compositions and methods for screening and identifying clinically aggressive prostate cancer,0,C12Q|G01N
11963966,2024-04-23,Compositions and methods for treating ovarian tumors,0,A61K|A61P|C12Q
11957739,2024-04-16,Compositions and methods for treating cancer using RHOA dominant negative forms,0,A61K|A61P|C07K|C12N|C12Y|G01N
11957713,2024-04-16,Compositions and methods for treating diseases and disorders of the central nervous system,0,A01K|A61K|A61P|C12N
11952432,2024-04-09,Cell-permeable stapled peptide modules for cellular delivery,0,A61K|C07K
11946105,2024-04-02,Bacterial etiology of colorectal cancer,0,C12Q
11945846,2024-04-02,Stapled intracellular-targeting antimicrobial peptides to treat infection,1,A61K|A61P|C07K|Y02A
11945816,2024-04-02,Inhibitors of EGFR and/or HER2 and methods of use,0,A61P|C07D
11944625,2024-04-02,"Calmodulin inhibitors, Chk2 inhibitors and RSK inhibitors for the treatment of ribosomal disorders and ribosomapathies",0,A61K|A61P
11932646,2024-03-19,Small molecule myristate inhibitors of Bcr-abl and methods of use,0,A61K|A61P|C07D|C07H|Y02A
11932625,2024-03-19,Inhibitors of cyclin-dependent kinase 12 (CDK12) and uses thereof,3,A61P|C07D
11926874,2024-03-12,"Methods for identification, assessment, prevention, and treatment of cancer using PD-L1 isoforms",0,A61P|C12N|C12Q|G01N
11913075,2024-02-27,Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer,0,A61K|A61P|C12Q|G01N
11904310,2024-02-20,High-throughput dynamic reagent delivery system,0,B01L|C12M|C12Q|G01N
11896678,2024-02-13,Compositions and methods for treatment of peroxisome proliferator-activated receptor gamma (PPARG) activated cancer,0,A61K|A61P|C12N|G01N
11884970,2024-01-30,Denaturation-enhanced DNA mutation testing for limited biological specimens,0,C12Q
11878019,2024-01-23,Uses of pyrimidopyrimidinones as SIK inhibitors,0,A61K|A61P
11874276,2024-01-16,STING levels as a biomarker for cancer immunotherapy,0,A61K|A61P|C07K|C12Q|G01N
11873486,2024-01-16,"Modulating dsRNA editing, sensing, and metabolism to increase tumor immunity and improve the efficacy of cancer immunotherapy and/or modulators of intratumoral interferon",0,A61K|C12N|C12Q
11867688,2024-01-09,High throughput BH3 profiling: a rapid and scalable technology to BH3 profile on low numbers of cells,0,G01N
11867687,2024-01-09,Methods of BH3 profiling,0,G01N
11865176,2024-01-09,Compositions and methods of modulating anti-tumor immunity,0,A61K|A61P|C07K
11858897,2024-01-02,"Substituted 6,11-dihydro-5H-benzo[b]carbazoles as inhibitors of ALK and SRPK",0,A61P|C07D|C12N|C12Y
11852631,2023-12-26,Biomarkers predictive of anti-immune checkpoint response,0,A61K|A61P|C07K|C12N|C12Q|G01N
11851472,2023-12-26,NKG2D-IG fusion protein for cancer immunotherapy,0,A61K|A61P|C07K
11845992,2023-12-19,Compositions and methods for predicting response and resistance to CDK4/6 inhibition,0,A61K|C12N|C12Q|C12Y|G16B|G16H
11845728,2023-12-19,Compounds and methods for treating cancer,0,A61P|C07D
11844800,2023-12-19,Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia,0,A61K|A61P|C07K|G01N
11834718,2023-12-05,"Compositions and methods for diagnosing, evaluating and treating cancer by means of the DNA methylation status",0,C12Q|G16B
11834520,2023-12-05,Selective targeting of apoptosis proteins by structurally-stabilized and/or cysteine-reactive NOXA peptides,0,A61K|C07K
11827704,2023-11-28,Antibody molecules to PD-1 and uses thereof,1,A61K|A61P|C07K|G01N|Y02A
11827636,2023-11-28,Degradation of cyclin-dependent kinase 8 (CDK8) by conjugation of CDK8 inhibitors with E3 ligase ligand and methods of use,0,A61K|A61P|C07D
11826365,2023-11-28,Type II raf kinase inhibitors,1,A61K|A61P|C07D
11820822,2023-11-21,Methods for sensitizing cancer cells to T cell-mediated killing by modulating molecular pathways,0,A61K|A61P|C07K|C12N|C12Q|G01N
11815508,2023-11-14,Dynamic BH3 profiling,0,G01N
11814379,2023-11-14,Cyano quinoline amide compounds as HER2 inhibitors and methods of use,0,A61P|C07D
11807895,2023-11-07,High-throughput drug and genetic assays for cellular transformation,0,C12M|C12N|C12Q|G01N
11807606,2023-11-07,Sulfonamide derivatives for protein degradation,0,A61K|A61P|C07C|C07D
11802132,2023-10-31,Small molecules for inducing selective protein degradation and uses thereof,0,A61K|A61P|C07D
11789025,2023-10-17,Reagents and methods for analysis of proteins and metabolites targeted by covalent probes,0,C07C|C07D|G01N
11789022,2023-10-17,MEK1 mutation conferring resistance to RAF and MEK inhibitors,0,A61K|A61P|C12N|C12Q|C12Y|G01N
11788151,2023-10-17,C-RAF mutants that confer resistance to RAF inhibitors,0,A61K|A61P|C12N|C12Q|C12Y|G01N
11773070,2023-10-03,Dihydrooxadiazinones,2,A61K|A61P|C07D
11771697,2023-10-03,Small molecule degraders of polybromo-1 (PBRM1),0,A61K|A61P|C07D
11767523,2023-09-26,Acrylamide copolymerization for sequestration and production of single-stranded nucleic acid,0,C08F|C08J|C12N|C12Q
11766471,2023-09-26,Compositions and methods for induced brown fat differentiation,0,A61K|A61P|C07H|C07K|C12N
11753434,2023-09-12,Compositions and methods for transient gene therapy with enhanced stability,0,A61K|A61P|C07H|C07K|C12N|C12P|C12Q
11740242,2023-08-29,Modulating biomarkers to increase tumor immunity and improve the efficacy of cancer immunotherapy,0,A01K|A61P|C12N|C12Q|G01N
11739385,2023-08-29,Discovery of a somatic mutation in MYD88 gene in lymphoplasmacytic lymphoma,1,A61K|C12Q
11730818,2023-08-22,Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use,0,A61K|A61P|C07D
11730810,2023-08-22,"Composition comprising an antigen and a substituted imidazo[1,2-a]pyrimidine for enhancing human immune response",0,A61K|C07D|C12N|Y02A
11725237,2023-08-15,Polymorphic gene typing and somatic change detection using sequencing data,0,C12Q|G16B
11725230,2023-08-15,Selective degradation of wild-type DNA and enrichment of mutant alleles using nuclease,0,C12N|C12P|C12Q
11725011,2023-08-15,Bicyclic urea kinase inhibitors and uses thereof,2,A61K|A61P|C07D
11723973,2023-08-15,Humanized CC chemokine receptor 4 (CCR4) antibodies and methods of use thereof,0,A61K|A61P|C07K
11723972,2023-08-15,"Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1",0,A61K|A61P|C07K
11712458,2023-08-01,Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use,0,A61K|A61P|C07D
11707481,2023-07-25,Compositions and methods of treating Fanconi Anemia,0,A61K|C12N
11702402,2023-07-18,Small molecules that block proteasome-associated ubiquitin receptor RPN13 function and uses thereof,0,A61K|A61P|C07D
11685954,2023-06-27,Biomarkers predictive of endocrine resistance in breast cancer,0,C12Q|G01N
11674950,2023-06-13,Methods determining and treating cellular resistance to ADP-rtbosylating toxin,0,A61K|C12N|G01N
11673956,2023-06-13,Anti-galectin-1 (Gal1) monoclonal antibodies and fragments thereof for neutralizing Gal1,0,A61K|A61P|C07K|G01N
11673891,2023-06-13,Imidazopyrimidine compounds and uses thereof,0,A61K|A61P|C07D|Y02A|Y02P
11673882,2023-06-13,Pyrimidines as EGFR inhibitors and methods of treating disorders,0,A61P|C07D
11666580,2023-06-06,Mechanism of resistance to bet bromodomain inhibitors,0,A61K|A61P|C07D|G01N
11644466,2023-05-09,"Methods for treating, preventing and predicting risk of developing breast cancer",0,G01N
11634450,2023-04-25,DOT1L degraders and uses thereof,1,A61P|C07H
11633415,2023-04-25,Compounds and methods useful for treating or preventing cancers,0,A61K
11624747,2023-04-11,Biomarkers for the early detection of breast cancer,0,C07K|C12Q|C12Y|C40B|G01N
11624093,2023-04-11,Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response,0,A61K|C12Q|G01N
11597934,2023-03-07,Methods and compositions for reducing immunosuppression by tumor cells,2,A61K|A61P|C07K|C12N|C12Q
11591403,2023-02-28,IL-23R antagonists to reprogram intratumoral T regulatory cells into effector cells,0,A61K|A61P|C07K|C12N|G01N
11590213,2023-02-28,Targeted expansion of Qa-1-peptide-specific regulatory CD8 T cells to ameliorate arthritis,0,A61K|C07K|C12N
11584788,2023-02-21,"Compositions and methods for identification, assessment, prevention, and treatment of melanoma using PD-L1 isoforms",0,A61K|A61P|C07K|C12Q|G01N
11584746,2023-02-21,Inhibitors of EGFR and methods of use thereof,0,A61P|C07D
11583586,2023-02-21,Methods to induce targeted protein degradation through bifunctional molecules,3,A61K|C07D|C07J|Y02A
11578075,2023-02-14,Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of use,0,A61K|A61P|C07D
11572590,2023-02-07,Methods for evaluating tumor cell spheroids using 3D microfluidic cell culture device,1,C12M|C12N|C12Q|C12Y|G01N
11567082,2023-01-31,"Compositions, assays, and methods for direct modulation of fatty acid metabolism",1,A61K|A61P|C07K|C12Y|G01N
11548936,2023-01-10,Compositions and methods for treating lysosomal storage diseases and disorders,0,A61K|A61P|C07K|C12N|G01N
11547614,2023-01-10,Methods and compositions for studying cell evolution,0,A41D|A61F|C12N
11542251,2023-01-03,IRAK degraders and uses thereof,1,A61K|A61P|C07D
11534471,2022-12-27,"Isolation, preservation, compositions and uses of extracts from justicia plants",0,A23C|A23J|A23L|A23V|A61K|A61P
11530219,2022-12-20,Ligands to cereblon (CRBN),1,A61P|C07D
11530209,2022-12-20,Small molecule inhibition of transcription factor SALL4 and uses thereof,0,A61K|A61P|C07D
11517591,2022-12-06,Immunogenic peptides specific to BCMA and TACI antigens,0,A61K|A61P|C07K
11505831,2022-11-22,Compositions and methods comprising digital signatures to predict response and resistance to targeted therapy and immunotherapy,0,C12Q
11505597,2022-11-22,Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof,0,A61K|C07K|C12N|G01N
11505560,2022-11-22,Heterobifunctional compounds with improved specificity,1,A61K|A61P|C07D
11492670,2022-11-08,Compositions and methods for targeting cancer-specific sequence variations,0,A61K|B82Y|C12N|C12Q
11492403,2022-11-08,"Anti-phosphotyrosinylated programmed death 1 (PD-1) monoclonal antibodies, methods of making and methods of using thereof",1,A61K|C07K|G01N
11485787,2022-11-01,Agents that modulate RGMb-neogenin-BMP signaling and methods of use thereof,0,A61K|C07K|C12N|G01N
11479878,2022-10-25,Methods for genome characterization,0,C12Q|C40B
11466064,2022-10-11,Bcl-w polypeptides and mimetics for treating or preventing chemotherapy-induced peripheral neuropathy and hearing loss,0,A61K|A61P|C07K
11459389,2022-10-04,Monoclonal antibodies that bind human CD161,2,A61P|C07K
11452768,2022-09-27,Combination therapy with neoantigen vaccine,4,A61K|A61P|C07K
11447559,2022-09-20,"Anti-BCMA antibody having high affinity for BCMA and pharmaceutical composition for treatment of cancer, comprising same",1,A61K|A61P|C07K|C12N
11447467,2022-09-20,Compounds for the degradation of STK4 and treatment of hematologic malignancies,0,A61P|C07D
11446309,2022-09-20,Combination therapy for cancer using bromodomain and extra-terminal (BET) protein inhibitors,0,A61K|A61P|C07D
11427553,2022-08-30,Dihydrooxadiazinones,4,A61K|A61P|C07D
11421218,2022-08-23,Methods for enhancing the efficiency of gene editing,0,C12N
11421032,2022-08-23,Compositions and methods for inhibition of MICA/B shedding,0,A61K|A61P|C07K|G01N
11414694,2022-08-16,Nucleic acid nanoswitch catenanes,1,B82Y|C12Q
11413340,2022-08-16,Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy,1,A61K|A61P
11413288,2022-08-16,Methods of treating cancers,2,A61K|A61P|C07K|C12N|C12Y|G01N
11406645,2022-08-09,Acetamide thienotriazolodiazepines and uses thereof,0,A61K|A61P|C07D|Y02A
11391739,2022-07-19,Compositions and methods for treating multiple myeloma,0,C12Q|G01N
11384126,2022-07-12,Compositions and methods for inhibiting DHHC-type palmitoyltransferases for cancer treatment,0,A61K|A61P|C07K|C12N|G01N
11382905,2022-07-12,Immunomodulation by IAP inhibitors,0,A61K|A61P|C12N
11377697,2022-07-05,Biomarkers predictive of anti-immune checkpoint response,1,A61K|C12Q|G01N
11377696,2022-07-05,PBRM1 biomarkers predictive of anti-immune checkpoint response,0,A61K|C07K|C12Q|G01N
11371989,2022-06-28,Intracellular osteopontin regulates the lineage commitment of lymphoid subsets,0,A61K|A61P|C12Q|G01N
11371090,2022-06-28,Compositions and methods for molecular barcoding of DNA molecules prior to mutation enrichment and/or mutation detection,1,C12Q
11369635,2022-06-28,LMP1-expressing cells and methods of use thereof,0,A01K|A61K|A61P|C07K|C12N
11366100,2022-06-21,P13K-MTORC1-S6K1 signaling pathway biomarkers predictive of anti-cancer responses,0,A61K|C12Q|G01N
11365177,2022-06-21,Chemical uncouplers of respiration and methods of use thereof,0,A61K|A61P|C07D
11359020,2022-06-14,Agents that modulate immune cell activation and methods of use thereof,0,A61K|A61P|C07K|G01N
11359013,2022-06-14,Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (PD-1) pathway,0,A61K|A61P|C07K|C12N|G01N|Y02A
11358960,2022-06-14,Pyrazol-3-ones that activate pro-apoptotic BAX,0,A61K|A61P|C07D
11340216,2022-05-24,Methods and compositions for the positive selection of protein destabilizers,0,C07K|C12N|C12Q|G01N
11339157,2022-05-24,"4H-pyrrolo[3,2-c]pyridin-4-one derivatives",0,A61K|A61P|C07D
11331379,2022-05-17,Compositions and methods for regulating pancreatic beta cell function using adipsin,0,A61K|C12Q|C12Y|G01N
11325955,2022-05-10,Stabilized anti-microbial peptides for the treatment of antibiotic-resistant bacterial infections,2,A61K|A61L|A61P|C07K|C12Q|Y02A
11325910,2022-05-10,Inhibitors of cyclin-dependent kinases,7,A61K|A61P|C07D|C07K
11318139,2022-05-03,Methods for treating brain metastases using combinations of anti-P13K and anti-mTOR agents,0,A61K|A61P|C07K|C12N
11311609,2022-04-26,Regulating chimeric antigen receptors,1,A61K|A61P|C07D|C07J|C07K|C12N|C12Y
11306105,2022-04-19,Cyano thienotriazolodiazepines and uses thereof,2,A61P|C07D
11306070,2022-04-19,Inhibitors of cyclin-dependent kinase 12 (CDK12) and uses thereof,7,A61P|C07D
11299782,2022-04-12,Methods for predicting anti-cancer response,0,C12Q|G01N
11298354,2022-04-12,Methods of use and pharmaceutical combinations of HDAC inhibitors with BET inhibitors,1,A61K|A61P
11293023,2022-04-05,Tunable endogenous protein degradation,0,A61K|A61P|C07K|C12N
11291706,2022-04-05,"Methods for identification, assessment, prevention, and treatment of metabolic disorders using Slit2",0,A61K|A61P|C07K|G01N
11285218,2022-03-29,Degradation of bromodomain-containing protein 9 (BRD9) by conjugation of BRD9 inhibitors with E3 ligase ligand and methods of use,2,A61K|A61P|C07D
11285158,2022-03-29,Uses of pyrimidopyrimidinones as SIK inhibitors,0,A61K|A61P
11285149,2022-03-29,Enhanced immunotherapy of cancer using targeted transcriptional modulators,0,A61K|A61P|C07K
11285144,2022-03-29,Use of CDK8 inhibitors to treat diseases of inflammation and autoimmunity,1,A61K|G01N|Y02A
11279707,2022-03-22,NEK inhibitors and methods of use,0,A61P|C07D
11261256,2022-03-01,Methods for depleting or inhibiting the migration of regulatory T-cells in early or late stages of cancer,0,A61K|A61P|C07K
11261251,2022-03-01,"Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor",0,A61K|A61P|C07K|Y02A
11254972,2022-02-22,Crisscross cooperative self-assembly,2,B82Y|C07H|C12Q
11254682,2022-02-22,Small molecule myristate inhibitors of Bcr-abl and methods of use,0,A61K|A61P|C07D|C07H|Y02A
11248007,2022-02-15,Inhibitors of MALT1 and uses thereof,0,A61P|C07D
11247991,2022-02-15,Degradation of cyclin-dependent kinase 8 (CDK8) by conjugation of CDK8 inhibitors with E3 ligase ligand and methods of use,0,A61K|A61P|C07D
11247970,2022-02-15,Selective inhibition of gluconeogenic activity,0,A61K|A61P|C07D
11241435,2022-02-08,Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis,1,A61K|A61P
11236082,2022-02-01,EZH2 inhibitors and uses thereof,0,A61P|C07D|G01N
11225520,2022-01-18,Immunotherapy compositions and methods,3,A61K|A61P|C07K|C12N
11225511,2022-01-18,BH3 peptides and methods of use thereof,3,A61P|C07K
11225469,2022-01-18,Inhibitors of phosphoglycerate dehydrogenase (PHGDH) and uses thereof,0,A61K|A61P|C07D
11224608,2022-01-18,Compounds and methods for treating cancer,1,A61K|A61P|C07D|C07H
11220548,2022-01-11,Treatment of C1013G/CXCR4-associated Waldenstrom's macroglobulinemia with an anti-CXCR4 antibody,0,A61K|A61P|C07K|C12Q
11220545,2022-01-11,Methods for upregulating immune responses using combinations of anti-RGMb and anti-PD-1 agents,1,A61K|A61P|C07K|C12N
11220532,2022-01-11,Targeting deregulated Wnt signaling in cancer using stabilized alpha-helices of BCL-9,0,A61K|A61P|C07K|G01N
11215608,2022-01-04,Methods of determining cellular chemosensitivity,3,A61P|C12N|C12Q|G01N
11214839,2022-01-04,Circulating microRNA signatures for ovarian cancer,1,A61P|C12Q|G16B
11214837,2022-01-04,Methods for predicting likelihood of responding to treatment,0,C12Q
11207393,2021-12-28,Regulatory T cell PD-1 modulation for regulating T cell effector immune responses,0,A01K|A61K|A61P|C07K
11207320,2021-12-28,Compositions and methods for cancer expressing PDE3A or SLFN12,0,A61K|A61P|G01N
11207278,2021-12-28,Agents for reversing toxic proteinopathies,1,A61K|A61P|C12Q|G01N
11191823,2021-12-07,Compositions and methods for treating arenavirus infection,0,A61K|A61P|C07K|C12N|G01N|G16B
11186874,2021-11-30,ERK1 and ERK2 mutations that confer resistance to MAPK pathway inhibitors,0,C12N|C12Q|C12Y
11186574,2021-11-30,Inhibitors of EGFR and/or HER2 and methods of use,0,A61P|C07D
11179480,2021-11-23,In vivo methods for identifying cancer-associated immunotherapy targets,0,A01K|A61K|C12N|G01N
11174511,2021-11-16,Methods and compositions for selecting and amplifying DNA targets in a single reaction mixture,0,C12Q
11174510,2021-11-16,Full COLD-PCR enrichment with reference blocking sequence,2,C12Q
11174323,2021-11-16,Method of treating renal cancer using carbonic anhydrase IX (G250) antibodies,2,A61K|A61P|C07K
11169155,2021-11-09,Reagents for quantitative mass spectrometry,1,C07B|C07C|C07D|C07K|G01N
11161842,2021-11-02,Bifunctional molecules for degradation of EGFR and methods of use,0,A61K|A61P|C07D
11155857,2021-10-26,Methods for measuring RNA translation rates,0,C12Q|C12Y
11155620,2021-10-26,Method of detecting TIM-3 using antibody molecules to TIM-3,5,A61K|A61P|C07K|G01N|Y02A
11155556,2021-10-26,Pyrimido-diazepinone kinase scaffold compounds and methods for treating PI3K-mediated disorders,0,A61K|A61P|C07D
11149069,2021-10-19,Compositions and methods for conformationally stabilizing primate immunodeficiency virus envelope glycoprotein trimers,0,A61K|C07K|C12N
11142554,2021-10-12,Selective Mcl-1 binding peptides,0,A61K|A61P|C07K
11142522,2021-10-12,"Compounds, compositions and methods for cancer treatment",1,A61K|A61P|C07D
11142507,2021-10-12,Inhibitors of cyclin-dependent kinases,6,A61K|A61P|C07D
11136410,2021-10-05,Antibodies against the MUC1-C/extracellular domain (MUC1-C/ECD),2,A61K|A61P|C07K
11136409,2021-10-05,"Compositions and methods for identification, assessment, prevention, and treatment of AML using USP10 biomarkers and modulators",0,A01K|A61K|A61P|C07K|C12Q|G01N
11136291,2021-10-05,Antifungal compounds and uses thereof,0,A61P|C07C|C07D
11135282,2021-10-05,Humanized influenza monoclonal antibodies and methods of use thereof,0,A61K|A61P|C07K
11130992,2021-09-28,Methods and compositions to enable multiplex COLD-PCR,0,C12Q
11129879,2021-09-28,Methods for the treatment of neurological disorders and diseases using FNDC5,0,A61K|C12Q|G01N
11124838,2021-09-21,Genetic abnormalities in plasma cell dyscrasias,0,A61P|C12Q|G01N
11124569,2021-09-21,Methods of reducing liver PD-1-expressing CD8+ T cells using PD-1 Fc fusion proteins that bind Fc receptors,0,A61K|A61P|C07K
11111296,2021-09-07,Compositions and methods for treating cardiac dysfunction,0,A61K|A61P|C07K|G16C
11105810,2021-08-31,Reagents for quantitative mass spectrometry,2,C07B|C07C|C07D|C07K|G01N
11104722,2021-08-31,Immunogenetic restriction on elicitation of antibodies,0,A61K|A61P|C07K|C12Q|G01N
11098369,2021-08-24,Methods for evaluating tumor cell spheroids using 3D microfluidic cell culture device,2,C12M|C12N|C12Q|C12Y|G01N
11098092,2021-08-24,Compositions and methods for brown fat induction and activity using FNDC5,0,A61K|C07K|C12N
11083783,2021-08-10,"XBP1, CD138, and CS1 peptides",0,A61K|A61P|C07K|Y02A
11078540,2021-08-03,Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy,0,A61K|A61P|C12N|C12Q|C12Y
11078246,2021-08-03,Peptides binding to Bfl-1,1,A61K|A61P|C07K|C12Q
11066708,2021-07-20,Compositions and methods for screening and diagnosis of prostate cancer,0,A61K|A61P|C12N|C12Q|G01N
11066363,2021-07-20,"Substituted 6,11-dihydro-5H-benzo[B]carbazoles as inhibitors of ALK and SRPK",0,A61P|C07D|C12N|C12Y
11060148,2021-07-13,Diagnosing and treating colorectal cancer,0,C12Q
11059801,2021-07-13,Methods to induce targeted protein degradation through bifunctional molecules,2,A61P|C07D|C07J
11058903,2021-07-13,Methods for identifying and treating cachexia or pre-cachexia using an inhibitor of rage,0,A61K|A61P|C07K|G01N
11052080,2021-07-06,Kinase inhibitors and methods of use thereof,1,A61K|A61P|C07D
11046954,2021-06-29,Targeted protein degradation to attenuate adoptive T-cell therapy associated adverse inflammatory responses,0,A61K|A61P|C07K|C12N
11046777,2021-06-29,Glucocorticoid-induced tumor necrosis factor receptor (GITR) antibodies and methods of use thereof,0,A61K|A61P|C07K
11046739,2021-06-29,BH4 stabilized peptides and uses thereof,3,A61K|C07K|G01N
11040957,2021-06-22,Heteroaromatic compounds useful for the treatment of proliferative diseases,6,A61K|A61P|C07D
11028089,2021-06-08,Pyrimido-diazepinone kinase scaffold compounds and methods of treating DCLK1/2-mediated disorders,0,A61K|A61P|C07D
11026921,2021-06-08,Compositions and methods of treating cancer,0,A61K|A61P|C12N
11021539,2021-06-01,Drug delivery compositions and uses thereof,4,A61K|A61L|A61P|C07H|C07K
11015223,2021-05-25,Methods for determining response to a hypomethylating agent,0,C12Q
11009508,2021-05-18,Methods of diagnosing and prognosing lung cancer,0,G01N
11008620,2021-05-18,Methods for treating cancer resistant to ErbB therapeutics,0,A61K|A61P|C12Q
11000547,2021-05-11,Compositions related to rna in circularized form,3,A61K|A61P|C07K|C12N
10993997,2021-05-04,Methods for profiling the t cell repertoire,4,A61K|C07K|C12N|C12Q|G01N
10993971,2021-05-04,Vaccination with MICA/B alpha 3 domain for the treatment of cancer,0,A61K|A61P|C07K|Y02A
10981990,2021-04-20,Antibody molecules to TIM-3 and uses thereof,10,A61K|A61P|C07K|G01N|Y02A
10981903,2021-04-20,Inhibitors of c-Jun-N-terminal kinase (JNK),3,A61K|A61P|C07D|Y02A
10980808,2021-04-20,"Calmodulin inhibitors, Chk2 inhibitors and RSK inhibitors for the treatment of ribosomal disorders and ribosomapathies",1,A61K|A61P
10975055,2021-04-13,Inhibitors of interleukin-1 receptor-associated kinases and uses thereof,0,A61P|C07D
10969394,2021-04-06,Reagents and methods for analysis of proteins and metabolites targeted by covalent probes,6,C07C|C07D|G01N
10968484,2021-04-06,Methods of identifying responses to map kinase inhibition therapy,0,A61K|C12Q|G01N
10966986,2021-04-06,"Compounds, compositions and methods for cancer patient stratification and cancer treatment",1,A61K|A61P|C07D|G01N
10960008,2021-03-30,Methods for treating PTEN deficient epithelial cancers using a combination of anti-PI3KBETA and anti-immune checkpoint agents,0,A01K|A61K|A61P|C07K|C12Q
10954242,2021-03-23,Bicyclic urea kinase inhibitors and uses thereof,7,A61K|A61P|C07D
10948492,2021-03-16,PD-L2 biomarkers predictive of PD-1 pathway inhibitor responses in esophagogastric cancers,0,C07K|C12Q|G01N
10947596,2021-03-16,"Compositions and methods for identification, assessment, prevention, and treatment of cancer using NFS1 biomarkers and modulators",0,C12Q|G01N
10934593,2021-03-02,Compositions and methods for predicting response and resistance to CDK4/6 inhibition,0,A61K|C12N|C12Q|C12Y|G16B|G16H
10934353,2021-03-02,Single agent anti-PD-L1 and PD-L2 dual binding antibodies and methods of use,1,A01K|A61P|C07K|G01N
10934256,2021-03-02,Compounds and methods for treating cancer,1,A61P|C07D
10927410,2021-02-23,"Compositions and methods for identification, assessment, prevention, and treatment of T-cell exhaustion using CD39 biomarkers and modulators",0,C12Q|G01N
10925967,2021-02-23,Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use,3,A61K|A61P|C07D
10925868,2021-02-23,Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of use,0,A61K|C07D
10914733,2021-02-09,High-throughput structure determination using nucleic acid calipers,1,C12Q|G01N
10913977,2021-02-09,Methods and compositions to enable enrichment of minor DNA alleles by limiting denaturation time in PCR or simply enable enrichment of minor DNA alleles by limiting the denaturation time in PCR,2,C12Q
10913752,2021-02-09,Bivalent bromodomain inhibitors and uses thereof,1,A61K|A61P|C07D|Y02A
10913744,2021-02-09,LRRK2 inhibitors and methods of making and using the same,0,A61P|C07D
10906889,2021-02-02,Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7),3,A61P|C07D|C07F
10906878,2021-02-02,Kinase inhibitors for the treatment of disease,0,A61K|A61P|C07D|Y02A
